<DOC>
	<DOCNO>NCT00532909</DOCNO>
	<brief_summary>To determine maximum tolerate dose Vandetanib current standard first-line chemotherapy regimen , capecitabine oxaliplatin without bevacizumab first line treatment metastatic colorectal cancer ( CRC ) define dose limit toxicity associate combination .</brief_summary>
	<brief_title>Phase I Vandetanib Plus Capecitabine , Oxaliplatin Bevacizumab Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Provision sign informed consent . Female male age 18 year . Negative pregnancy test woman childbearing potential . Histologically cytologically confirm adenocarcinoma colon rectum . Patients history colorectal adenocarcinoma treat surgical resection develop radiological clinical evidence metastatic cancer require separate histological cytological confirmation metastatic disease unless interval &gt; 5 year elapse primary surgery development metastatic disease . Clinicians consider biopsy lesion establish diagnosis metastatic colorectal adenocarcinoma substantial clinical ambiguity regard nature source apparent metastasis . A primary metastatic lesion measurable least one dimension RECIST criterion within 4 week prior entry study WHO performance status 02 Laboratory value &lt; = 2 week prior randomization : Absolute Neutrophil Count ( ANC ) &gt; =1.5 x 10^9/L ( &gt; =1500/mm^3 ) Platelets ( PLT ) &gt; =100 x 10^9/L ( &gt; =100,000/mm^3 ) Hemoglobin ( Hgb ) &gt; =9 g/dL Serum creatinine &lt; =1.5 x ULN Serum bilirubin &lt; =1.5 x ULN Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) &lt; =2.5 x ULN ( &lt; =5 x ULN liver metastasis present ) . Note : ERCP percutaneous stenting may use normalize liver function test . Negative trace proteinuria base dip stick reading OR , documentation +1 result protein dip stick reading , total urinary protein &lt; =500 mg measure creatinine clearance ( CrCl ) &gt; =50 mL/min 24hour urine collection • Life expectancy &gt; 12 week • Laboratory result : Serum bilirubin &gt; 1.5 x upper limit reference range ( ULRR ) Serum creatinine &gt; 1.5 x ULRR creatinine clearance &gt; = 50 mL/minute ( calculate CockcroftGault formula . ) Potassium &lt; 4.0 mmol/L despite supplementation ; serum calcium ( ionize adjust albumin , ) magnesium normal range despite supplementation . Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2.5 x ULRR alkaline phosphatase ( ALP ) &gt; 2.5 x ULRR , &gt; 5x ULRR judge investigator relate liver metastases Evidence severe uncontrolled systemic disease concurrent condition Investigator 's opinion make undesirable patient participate trial would jeopardize compliance protocol . Clinically significant cardiac event myocardial infarction ; New York Heart Association ( NYHA ) classification heart disease &gt; = 2 within 3 month entry ; presence cardiac disease , opinion Investigator , increase risk ventricular arrhythmia . History arrhythmia ( multifocal premature ventricular contraction ( PVCs ) , bigeminy , trigeminy , ventricular tachycardia , uncontrolled atrial fibrillation ) symptomatic require treatment ( CTCAE grade 3 ) asymptomatic sustain ventricular tachycardia . Atrial fibrillation , control medication , exclude . Previous history QTc prolongation result medication require discontinuation medication . Congenital long QT syndrome , 1st degree relative unexplained sudden death 40 year age . Presence leave bundle branch block ( LBBB . ) QTc Bazett 's correction unmeasurable , &lt; 480 msec screen ECG . If patient QTc &gt; = 480 msec screen ECG , screen ECG may repeat twice ( least 24 hour apart ) . The average QTc three screen ECGs must &lt; 480 msec order patient eligible study . ) Any concomitant medication may cause QTc prolongation , induce Torsades de Pointes induce CYP3A4 function Hypertension control medical therapy ( systolic blood pressure great 160 mm Hg diastolic blood pressure great 100 mm Hg ) Currently active diarrhea may affect ability patient absorb vandetanib tolerate diarrhea . Women currently pregnant breastfeeding . Previous current malignancy histology within last 5 year , exception cervical carcinoma situ adequately treat basal cell squamous cell carcinoma skin Receipt investigational agent within 30 day prior commence study treatment Last dose prior chemotherapy discontinue less 4 week start study therapy Last radiation therapy within last 4 week start study therapy , except palliative radiotherapy Any unresolved toxicity great CTC grade 1 previous anticancer therapy Previous enrollment randomization treatment present study Major surgery within 4 week , incompletely heal surgical incision start study therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>